Faecal calprotectin: factors affecting levels and its potential role as a surrogate marker for risk of development of Crohn’s Disease

English version České info

Background:
Faecal calprotectin (FC) is one of the most widely used non-invasive tests for the diagnosis and assessment of Crohn’s disease (CD) activity. Despite this, factors other than disease activity which affect levels have not been extensively reviewed. This is of importance when using FC in the diagnostic setting but also may be of utility in studying the aetiology of disease.

Objectives:
Our review outlines environmental risk factors that affect FC levels influencing diagnostic accuracy and how these may be associated with risk of developing CD. FC as a surrogate marker could be used to validate risk factors established in case control studies where prospective studies are not feasible. Proof of this concept is provided by our identification of obesity as being associated with elevated FC, our subsequent confirmation of obesity as risk factor for CD and the subsequent verification in prospective studies, as well as associations of lack of physical activity and dietary fibre intake with elevated FC levels and their subsequent confirmation as risk factors in prospective studies.

Conclusion:
We believe that FC is likely to prove a useful surrogate marker for risk of developing CD. This review has given a theoretical basis for considering the epidemiological determinants of CD which to date has been missing.

Keywords:
Crohn’s disease, Calprotectin, Surrogate marker, Environment, Diet

Autoři: Michael A. Mendall ¹; Derek Chan ²; Roshani Patel ³; Devinder Kumar ^3*
Působiště autorů: Department of Gastroenterology, Croydon University Hospital, 5 0 London Road, Surrey CR7 7YE, UK. ¹; Department of Gastroenterology, Blackshaw Road, London SW17 0QT, UK. ²; Department of Colorectal Surgery, St George’s Hospital, Blackshaw Road, London SW17 0QT, UK. ³
Vyšlo v časopise: BMC Gastroenterology 2016, 16:126
Kategorie: Debate
prolekare.web.journal.doi_sk: https://doi.org/10.1186/s12876-016-0535-z

© 2016 The Author(s).

Open access
This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
The electronic version of this article is the complete one and can be found online at: http://bmcgastroenterol.biomedcentral.com/articles/10.1186/s12876-016-0535-z

Souhrn

Keywords:
Crohn’s disease, Calprotectin, Surrogate marker, Environment, Diet

Zdroje

1. Khor B, Gardet A, Xavier RJ. Genetics and pathogenesis of inflammatory bowel disease. Nature. 2011;474(7351):307–17.

2. Vardulaki K, Langham J, Chandramohan D. Introduction to epidemiology. London: Open University Press; 2005 Ch7, p75.

3. Kaplan GG. Does consuming the recommend daily level of fiber prevent Crohn’s disease? Gastroenterology. 2013;5(145):925–7.

4. Noble CL, Arnott IDR. What is the risk that a child will develop inflammatory bowel disease if 1 or both parents have IBD? Inflamm Bowel Dis. 2008;14:S22–3.

5. Thjodleifsson B, et al. Subclinical intestinal inflammation: an inherited abnormality in Crohn’s disease relatives? Gastroenterology. 2003;124(7):1728–37.

6. Ahmad T, Satsangi J, McGovern D, Bunce M, Jewell DP. The genetics of inflammatory bowel disease. Aliment Pharmacol Ther. 2001;15:731–48.

7. Wright EK, et al. Measurement of Fecal Calprotectin Improves Monitoring and Detection of Recurrence of Crohn’s Disease After Surgery. Gastroenterology. 2015;148(5):938–47.

8. Ananthakrishnan AN. Epidemiology and risk factors for IBD. Nat Rev Gastroenterol Hepatol. 2015;12(4):205–17.

9. Tibble J, Teahon K, Thjodleifsson B, et al. A simple method for assessing intestinal inflammation in Crohn’s disease. Gut. 2000;47(4):506–13.

10. Costa F, Mumolo MG, Bellini M, et al. Role of faecal calprotectin as noninvasive marker of intestinal inflammation. Dig Liver Dis. 2003;35(9):642–7.

11. Røseth AG, Aadland E, Grzyb K. Normalization of faecal calprotectin: a predictor of mucosal healing in patients with inflammatory bowel disease. Scand J Gastroenterol. 2004;39(10):1017.

12. Vermeire S, Van Assche G, Rutgeerts P. Laboratory markers in IBD: useful, magic, or unnecessary toys? Gut. 2006;55(3):426–31.

13. Van Rheenen PF, Van de Vijver E, Fidler V. Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: diagnostic meta-analysis. BMJ. 2010;341:c3369.

14. Mao R, Gao X, et al. Fecal calprotectin in predicting relapse of inflammatory bowel diseases: A meta-analysis of prospective studies. Inflamm Bowel Dis. 2012;18(10):1894–9.

15. Lewis JD. The utility of biomarkers in the diagnosis and therapy of inflammatory bowel disease. Gastroenterology. 2011;140(6):1817–26.

16. Tibble JA, Sigthorsson G, Bridger S, et al. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology. 2000;119(1):15–22.

17. García-Sánchez V, Iglesias-Flores E, Gonzalez R, et al. Does fecal calprotectin predict relapse in patients with Crohn’s disease and ulcerative colitis? J Crohns Colitis. 2010;4(2):144–52.

18. Konikoff MR, Denson LA. Role of fecal calprotectin as a biomarker of intestinal inflammation in inflammatory bowel disease. Inflamm Bowel Dis. 2006;12(6):524–34.

19. Poullis A, Foster R, Shetty A, et al. Bowel inflammation as measured by fecal calprotectin a link between lifestyle factors and colorectal cancer risk. Cancer Epidemiol Biomarkers Prev. 2004;13(2):279–84.

20. Poullis A, Foster R, Mendall MA. Proton pump inhibitors are associated with elevation of faecal calprotectin and may affect specificity. Eur J Gastroenterol Hepatol. 2003;15(5):573–4.

21. Brignardello J, Morales P, Diaz E, et al. Pilot study: alterations of intestinal microbiota in obese humans are not associated with colonic inflammation or disturbances of barrier function. Aliment Pharmacol Ther. 2010;32(11–12):1307–14.

22. Spagnuolo MI, Cicalese MP, Caiazzo MA, et al. Relationship between severe obesity and gut inflammation in children: whatLs next? 2010.

23. Kant P, Fazarkerley R, Hull MA. Faecal calprotectin levels before and after weight loss in obese and overweight subjects. Int J Obes (Lond). 2013;37(2):317–9.

24. Verdam FJ, Fuentes S, de Jonge C, et al. Human intestinal microbiota composition is associated with local and systemic inflammation in obesity. Obesity. 2013;21(12):E607–15.

25. Ma Y, Griffith JA, Chanson-Taber L, et al. Association between dietary fiber and serum C-reactive protein. Am J Clin Nutr. 2006;83(4):760–6.

26. Gentschew L, Ferguson LR. Role of nutrition and microbiota in susceptibility to inflammatory bowel diseases. Mol Nutr Food Res. 2012;56(4):524–35.

27. Gregor MF, Hotamisligrl GS. Inflammatory mechanisms in obesity. Annu Rev Immunol. 2011;29:415–45.

28. Collins SM, Bercik P. The relationship between intestinal microbiota and the central nervous system in normal gastrointestinal function and disease. Gastroenterology. 2009;136(6):2003–14.

29. Clarke SF, Murphy EF, O’Sullivan O, et al. Exercise and associated dietary extremes impact on gut microbial diversity. Gut. 2014;63(12):1913–20. gutjnl-2013.

30. Hold G. The gut microbiota, dietary extremes and exercise. Gut. 2014;63(12):1838–9.

31. Teixeira TFS, et al. Intestinal permeability parameters in obese patients are correlated with metabolic syndrome risk factors. Clin Nutr. 2012;31(5):735–40.

32. Aujnarain A, Mack DR, Benchimol EI. The role of the environment in the development of pediatric inflammatory bowel disease. Curr Gastroenterol Rep. 2013;15(6):1–11.

33. Lakatos PL, Burisch J. Environment and invironment in IBDs: partners in crime. Gut. 2015;64:1009–10.

34. Ananthakrishnan AN, Higuchi LM, Huang ES, et al. Aspirin, nonsteroidal antiinflammatory drug use, and risk for Crohn disease and ulcerative colitis: a cohort study. Ann Intern Med. 2012;156(5):350–9.

35. Ananthakrishnan AN, Khalili H, Konijeti GG, et al. A prospective study of long-term intake of dietary fiber and risk of Crohn’s disease and ulcerative colitis. Gastroenterology. 2013;145(5):970–7.

36. Ananthakrishnan AN, Khalili H, Konijeti GG, et al. Long-term intake of dietary fat and risk of ulcerative colitis and Crohn’s disease. Gut. 2014;63(5):776–84.

37. Chan SS, Luben R, Olsen A, et al. Body mass index and the risk for Crohn’s disease and ulcerative colitis: data from a European Prospective Cohort Study (The IBD in EPIC Study). Am J Gastroenterol. 2013;108(4):575–82.

38. Chan SS, Luben R, Bergmann MM, et al. Aspirin in the aetiology of Crohn’s disease and ulcerative colitis: a European prospective cohort study. Aliment Pharmacol Ther. 2011;34(6):649–55.

39. Khalili H, Ananthakrishnan AN, Konijeti GG, et al. Physical activity and risk of inflammatory bowel disease: prospective study from the Nurses’ Health Study cohorts. BMJ. 2013;347:f6633.

40. Khalili H, Ananthakrishnan AN, Higuchi LM, et al. 222 Measures of adiposity and risk of Crohn’s disease and ulcerative colitis. Gastroenterology. 2013;5(144):S-48.

41. Swinburn BA, Sacks G, Hall KD, et al. The global obesity pandemic: shaped by global drivers and local environments. The Lancet. 2011;378(9793):804–14.

42. Mendall MA, Gunasekera AV, John BJ, et al. Is obesity a risk factor for Crohn’s disease? Dig Dis Sci. 2011;56(3):837–44.

43. Harpsøe MC, Basit S, Andersson M et al. Body mass index and risk of autoimmune diseases: a study within the Danish National Birth Cohort. Int J Epidemiol. 2014;43:843–55

44. Satsangi J, Silverberg MS, Vermeire S, Colombel J. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut. 2006;55(6):749–53.

45. Spooren CE, Pierik MJ, Zeegers MP, et al. Review article: the association of diet with onset and relapse in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2013;38(10):1172–87.

46. Hansen TS, Jess T, Vind I, et al. Environmental factors in inflammatory bowel disease: a case-control study based on a Danish inception cohort. J Crohns Colitis. 2011;5(6):577–84.

47. Hou JK, Abraham B, El-Serag H. Dietary intake and risk of developing inflammatory bowel disease: a systematic review of the literature. Am J Gastroenterol. 2011;106(4):563–73.

48. Sonnenberg A. Occupational distribution of inflammatory bowel disease among German employees. Gut. 1990;31(9):1037–40.

49. Boggild H, Tuchen F, Orhede E. Occupation, employment status and chronic inflammatory bowel disease in Denmark. Int J Epidemiol. 1996;25(3):630–7.

50. Persson PG, Leijonmarck CE, Bernell O, et al. Risk indicators for inflammatory bowel disease. Int J Epidemiol. 1993;22(2):268–72.

51. Klein I, Reif S, Farbstein H, et al. Preillness non dietary factors and habits in inflammatory bowel disease. Ital J Gastroenterol Hepatol. 1998;30(3):247–51.

52. Dam AN, Berg AM, Farraye FA, et al. Environmental influences on the onset and clinical course of Crohn’s disease—Part 1: An overview of external risk factors. Gastroenterol Hepatol. 2013;9(11):711.

53. Mahid SS, Minor KS, Soto RE, et al. Smoking and inflammatory bowel disease: a meta-analysis. May Clin Proc. 2006;81(11):1462–71. Elsevier.

54. Juilerat J, Schneeweiss S, Cook EF, et al. Drugs that inhibit gastric acid secretion may alter the course of inflammatory bowel disease. Aliment Pharmacol Ther. 2012;36(3):239–47.

55. Han YM, Koh SJ, Kim JW, et al. P125 The effect of suppressing gastric acid secretion in Crohn’s disease. J Crohns Colitis. 2014;8:S114–5.